Otsuka Pharmaceutical

New Capabilities

Markets Voyxact, the first FDA-approved APRIL inhibitor for IgAN

For decades, doctors had no drugs specifically approved for IgA nephropathy, a kidney disease that pushes up to half of patients toward kidney failure within ten years of diagnosis. Since December 2021, the FDA has approved five.

Updated Jun 1